1. Is dose modification or discontinuation of nilotinib necessary in nilotinib-induced hyperbilirubinemia?
   You-Wen Tan, 2021, World Journal of Meta-Analysis CrossRef
2. Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy
   Xun Cai et al, 2017, Cancer Biology & Therapy CrossRef